[go: up one dir, main page]

WO2013036031A3 - Pharmaceutical composition including a microrna486 expression inhibitor as an active ingredient for preventing and treating neurological disorders - Google Patents

Pharmaceutical composition including a microrna486 expression inhibitor as an active ingredient for preventing and treating neurological disorders Download PDF

Info

Publication number
WO2013036031A3
WO2013036031A3 PCT/KR2012/007112 KR2012007112W WO2013036031A3 WO 2013036031 A3 WO2013036031 A3 WO 2013036031A3 KR 2012007112 W KR2012007112 W KR 2012007112W WO 2013036031 A3 WO2013036031 A3 WO 2013036031A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
neurological disorders
pharmaceutical composition
treating neurological
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/007112
Other languages
French (fr)
Korean (ko)
Other versions
WO2013036031A2 (en
Inventor
강수경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Publication of WO2013036031A2 publication Critical patent/WO2013036031A2/en
Publication of WO2013036031A3 publication Critical patent/WO2013036031A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition including a miRNA486 expression inhibitor as an active ingredient for preventing and treating neurological disorders. More particularly, since it has been verified that interference with the expression of miR486 using an miR486 inhibitor overcomes the inhibition of NeuroD6, thereby inducing improvements in spinal cord injuries (SCI), the miR486 inhibitor can be used as an active ingredient in a pharmaceutical composition for preventing and treating neurological disorders, and further, the mechanism by which miR486 controls the expression of NeuroD6 can be applied in screening for candidate materials for preventing and treating neurological disorders.
PCT/KR2012/007112 2011-09-06 2012-09-05 Pharmaceutical composition including a microrna486 expression inhibitor as an active ingredient for preventing and treating neurological disorders Ceased WO2013036031A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0090424 2011-09-06
KR1020110090424A KR20130026950A (en) 2011-09-06 2011-09-06 Pharmaceutical composition comprising inhibitors of mir486 for the prevention and treatment of neuropathic disease

Publications (2)

Publication Number Publication Date
WO2013036031A2 WO2013036031A2 (en) 2013-03-14
WO2013036031A3 true WO2013036031A3 (en) 2013-07-11

Family

ID=47832704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007112 Ceased WO2013036031A2 (en) 2011-09-06 2012-09-05 Pharmaceutical composition including a microrna486 expression inhibitor as an active ingredient for preventing and treating neurological disorders

Country Status (2)

Country Link
KR (1) KR20130026950A (en)
WO (1) WO2013036031A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304041B1 (en) 2019-12-24 2021-09-24 경북대학교 산학협력단 Composition for preventing or treating inflammatory diseases comprising microrna inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100049079A (en) * 2007-07-18 2010-05-11 더 리젠트스 오브 더 유니버시티 오브 콜로라도 Differential expression of micrornas in nonfailing versus failing human hearts
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100049079A (en) * 2007-07-18 2010-05-11 더 리젠트스 오브 더 유니버시티 오브 콜로라도 Differential expression of micrornas in nonfailing versus failing human hearts
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOHAMMAD M. GHAHRAMANI SENO ET AL.: "Gene and miRNA expression profiles in autism spectrum disorders", BRAIN RESEARCH, vol. 1380, 22 March 2011 (2011-03-22), pages 85 - 97, XP028161669 *

Also Published As

Publication number Publication date
KR20130026950A (en) 2013-03-14
WO2013036031A2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2014144100A3 (en) Sgc stimulators
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
IN2014DN09804A (en)
WO2011090270A3 (en) Composition containing osmotin for preventing and treating neurological disorders
IL195217A0 (en) Protein kinase inhibitors and uses thereof
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2013170072A3 (en) Compounds for the treatment of neurological disorders
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
MX2016013037A (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders.
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2016040952A3 (en) BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
HK1213175A1 (en) Treatment and/or prophylaxis of tspo mediated diseases and/or disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829806

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12829806

Country of ref document: EP

Kind code of ref document: A2